Cosmos Health Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $73.7M+35.5% YoYTTM through 30 Jun 2026
Net Income -$24.4MTTM through 30 Jun 2026
Free Cash Flow -$9.9MTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| Gross Margin | 12.1% |
| EBITDA Margin | -23.0% |
| Operating Margin | -25.6% |
| Net Margin | -33.1% |
Returns
-103.9%ROE
-29.2%ROA
Balance Sheet Health
Debt / Equity0.91x
Current Ratio1.00x
Net Debt$13.3M
Cash & Equivalents$1.8M
Quality Metrics
Altman Z-Score-2.46
Piotroski F-Score4 / 9
FCF Margin-13.5%
Rule of 400.9
Earnings-Beat Rate0.0%
Multi-Year Trend
RevenueFY2025: $65.3M
Diluted EPS-$0.67TTMFY2025: $-0.63
Dividend
No dividend
Capital Allocation
R&D Spend$497.6K
Capex Intensity0.1%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Wholesale Distribution | View detailsContinued expansion of the pharmacy network and investments in automation (GDP-licensed distribution including ROWA robotics) to enhance logistics and fulfillment capabilities. | ||
| Contract Manufacturing | View detailsScaling contract manufacturing division to drive higher-margin product mix. | ||
| Proprietary Brands | View detailsGlobal expansion of proprietary brands, including Sky Premium Life, C-Scrub, and C-Sept, with the U.S. serving as a new growth engine. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.